Botulism

Botulism is a rare, neurotoxin-mediated disease caused by botulinum neurotoxin, which is produced by the anaerobic, gram-positive bacterium Clostridium botulinum and, rarely, by related species such as C. baratii and C. butyricum ^[1]. The disease is defined by toxin-mediated neuromuscular dysfunction rather than by invasive bacterial disease, and BoNT is identified as the primary virulence factor and causative agent ^[2]. The available sources also classify botulism according to the nature of intoxication, including foodborne, wound, infant, adult intestinal colonization, and iatrogenic forms ^[1][2].

Clinically, botulism is characterized by flaccid descending paralysis that begins with cranial nerve palsies and may progress to extremity weakness and respiratory failure ^[1]. The syndrome is described as symmetrical and potentially fatal if untreated, with respiratory failure and death noted as major adverse outcomes ^[2]. Neurologic manifestations are reported to be similar regardless of exposure route ^[1]. The provided sources do not give additional source-backed detail on symptom timing, fever pattern, or recovery course ^[1][2].

The provided material identifies botulism as a rare disease, but does not supply incidence estimates, geographic distribution, or case counts ^[1]. It is linked to several exposure contexts: ingestion of toxin in foodborne botulism, bacterial colonization of a wound, intestinal colonization in infant botulism and adult intestinal colonization botulism, and high-concentration cosmetic or therapeutic toxin injections in iatrogenic botulism ^[1]. One source notes that disease transmission is often facilitated by metabolically dormant spores that are highly resistant to environmental stress, allowing persistence in unfavorable conditions ^[2]. The same source also notes concern about intentional contamination of food or drink or aerosolization in a bioterrorism event, but provides no outbreak data ^[1].

Exposure occurs through ingestion of preformed toxin, colonization of a wound by bacteria, colonization of the intestines, or iatrogenic exposure through high-concentration cosmetic or therapeutic toxin injections ^[1]. Another source indicates that transmission is often facilitated by spores that persist in the environment and, in infant and wound botulism, germinate into neurotoxin-producing vegetative cells ^[2]. The provided sources do not further specify person-to-person spread, vector involvement, or other routes ^[1][2].

The provided snippets do not enumerate formal risk groups for botulism, so source-backed detail is limited ^[1][2]. They do identify infants in the context of infant botulism and patients with wound exposure, intestinal colonization, or recent high-concentration cosmetic or therapeutic toxin injections as exposure-relevant groups ^[1]. A separate source notes that neurologic diseases such as myasthenia gravis and Guillain-Barré syndrome can overlap clinically with botulism, but this is not presented as a risk factor ^[1].

The source material does not provide a formal prevention section, so source-backed detail on routine preventive measures is not yet available ^[1][2]. The available text does indicate that exposure can arise from contaminated food or drink, environmental spores, wound colonization, and iatrogenic toxin injections, which implies that prevention would need to address those exposure pathways, but no specific control recommendations are stated in the snippets ^[1][2]. Bioterrorism-related contamination or aerosolization is mentioned as a concern, but no prevention protocol is described ^[1].

In surveillance settings, botulism should be interpreted as a rare but severe neurotoxin-mediated syndrome with potential for respiratory failure, so even isolated compatible cases are epidemiologically important ^[1][2]. The sources emphasize multiple exposure categories, including foodborne, wound, infant, intestinal colonization, and iatrogenic disease, which may require different exposure investigations ^[1]. The available material also notes overlap with other neurologic diseases such as myasthenia gravis and Guillain-Barré syndrome, but does not provide diagnostic guidance ^[1]. Source-backed detail on routine reporting thresholds or standardized case definitions is not yet available ^[1][2].

1. 1 Rao AK et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021 May 7. PMID: 33956777. doi: 10.15585/mmwr.rr7002a1. PubMed: https://pubmed.ncbi.nlm.nih.gov/33956777/
2. 2 Rawson AM et al. Pathogenicity and virulence of Clostridium botulinum. Virulence. 2023 Dec. PMID: 37157163. doi: 10.1080/21505594.2023.2205251. PubMed: https://pubmed.ncbi.nlm.nih.gov/37157163/
3. 3 Dong M et al. Botulinum and Tetanus Neurotoxins. Annu Rev Biochem. 2019 Jun 20. PMID: 30388027. doi: 10.1146/annurev-biochem-013118-111654. PubMed: https://pubmed.ncbi.nlm.nih.gov/30388027/
4. 4 Botulism and Infant Botulism. Red Book Atlas of Pediatric Infectious Diseases. 2020. doi: 10.1542/9781610023511-31. DOI: https://doi.org/10.1542/9781610023511-31
5. 5 Botulism and Infant Botulism. Red Book Atlas of Pediatric Infectious Diseases. 2023. doi: 10.1542/9781610026314-31. DOI: https://doi.org/10.1542/9781610026314-31
6. 6 Botulism. Encyclopedia of the Neurological Sciences. 2014. doi: 10.1016/b978-0-12-385157-4.00609-6. DOI: https://doi.org/10.1016/b978-0-12-385157-4.00609-6

ICD-10

ICD-11

Total cases

470

Peak month

2009-04

Coverage

7 reporting countries · 2000-01-01 → 2024-12-01